Lilly's GLP-1 Pill Foundayo Gains FDA Approval—Obesity Pill Era Formally Begins

FDA approved Lilly's once-daily GLP-1 pill Foundayo on April 1, with LillyDirect shipments commencing mid-April. In 72-week trials, the highest-dose cohort achieved 12% weight loss versus 0.9% for placebo. Pricing: $50/month for Medicare, $25 with insured coupons, $149–349 without coverage. Novo's Wegovy pill posted 600,000+ prescriptions in March. The obesity market is shifting decisively from injectables to pills.